Description
WZ4002 inhibits EGFR in a variety of cell lines, including those harboring the T790M gatekeeper mutation. WZ2004 exhibits anticancer chemotherapeutic activity, inhibiting proliferation of lung adenocarcinoma cells and suppressing tumor growth in animal models.
|
Cas No. |
1213269-23-8 |
Product ID |
W9600 |
Product Name |
WZ4002 |
Formula |
C25H27ClN6O3 |
Formula Wt. |
494.97 |
Purity |
≥98% |
Store Temp |
-20°C |
References |
Nakagawa T, Takeuchi S, Yamada T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012 Oct;11(10):2149-57. PMID: 22844075.
Sakuma Y, Yamazaki Y, Nakamura Y, et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 2012 Mar;92(3):371-83. PMID: 22157722. |
|